Last reviewed · How we verify
NVP
NVP is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.
NVP is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection as part of combination antiretroviral therapy.
At a glance
| Generic name | NVP |
|---|---|
| Also known as | Nevirapine |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
NVP binds directly to HIV reverse transcriptase and inhibits its enzymatic activity, preventing the conversion of viral RNA into DNA and thus blocking HIV replication. It is used as part of combination antiretroviral therapy (cART) in HIV-infected patients. The drug has been a cornerstone of HIV treatment regimens, particularly in resource-limited settings.
Approved indications
- HIV-1 infection as part of combination antiretroviral therapy
Common side effects
- Rash
- Stevens-Johnson syndrome
- Hepatotoxicity
- Nausea
- Headache
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- POC HIV Testing and Early DTG Use for Infants (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (PHASE1)
- Promotion and Mitigation Factors Leading to Illegal Tobacco Purchases (NA)
- Functional Outcomes in CondUction System Pacing and Right Ventricular Synchrony (FOCUS-Right) (NA)
- Effects of a Low Nicotine Standard and Tobacco Prices on Illegal Cigarette Purchasing (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVP CI brief — competitive landscape report
- NVP updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI